Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma

Mayo Clinic Proceedings

Volumn 74, Issue 2, 1999, Pages 137-145

  Buckner, Jan C ^a   Malkin, Mark G ^a   Reed, Eddie ^a   Cascino, Terrence L ^a   Reid, Joel M ^a   Ames, Matthew M ^a   Tong, William P Y ^a   Lim, Silam ^a   Figg, William D ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLACETAMIDO 2,6 PIPERIDINEDIONE; ANTINEOPLASTON AS2-1; NSC 620261; NSC 648539; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; GLIOBLASTOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; SEIZURE; SOMNOLENCE;

EID: 0033048015     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.2.137     Document Type: Article

References (23)

1. Green S. 'Antineoplastons': an unproved cancer therapy. JAMA 1992;267:2924-2928
2. Burzynski SR, Kubove E, Burzynski B. Phase II clinical trials of antineoplaston AlO and AS2-1 infusions in astrocytoma. In: Adam D, Buchner T, Rubinstein E, editors. Recent Advances in Chemotherapy. Munich: Futuramed Publishers; 1991. pp 2506-2507
3. Antineoplastons: request for phase II trials in CNS malignancies. CTEP Lett 1992 May;10:10
4. Samid D, Shack S, Sherman LT. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res 1992;52:1988-1992
5. Samid D, Ram Z, Hudgins WR, Shack S, Liu L, Walbridge S, et al. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res 1994;54:891-895
6. Stockhammer G, Manley GT, Johnson R, Rosenblum MK, Samid D, Lieberman FS. Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate. J Neurosurg 1995:83:672-681
7. Samid D, Yen T-J, Shack S. Interferon in combination with antitumourigenic phenyl derivatives: potentiation of IFNa activity invitro. BrJHaematol 1991;79(Suppl l):81-83
8. Ram Z, Samid D, Walbridge S, Oshiro EM, Viola JJ, Tao-Cheng JH, et al. Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. Cancer Res 1994:54:2923-2927
9. Danes! R, Nardini D, Basolo F, Del Tacca M, Samid D, Myers CE. Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Mol Pharmacol 1996;49:972-979
10. Hudglns WR, Shack S, Myers CE, Samid D. Cytostatic activity of phenylacetate and derivatives against tumor cells: correlation with lipophilicity and inhibition of protein prenylation. Biochem Pharmacol 1995:50:1273-1279
11. Liu L, Hudgins WR, Miller AC, Chen LC, Samid D. Transcriptional upregulation of TGF-alpha by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cells. Cytokine 1995:7:449-456
12. Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumours of the Central Nervous System. 2nd ed. Berlin: SpringerVerlag; 1993
13. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982:38:143-151
14. Brusilow SW. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr Res 1991;29:147-150
15. Thibault A, Figg WD, McCall N, Samid D, Myers CE, Cooper MR. A simultaneous assay of the differentiating agents, phenylacetic acid and phenylbutyric acid, and one of their metabolites, phenylacetylglutamine, by reversed-phase, high performance liquid chromatography. J Liquid Chromatogr 1994:17:2895-2900
16. Sherwin CP, Kennard KS. Toxicity of phenylacetic acid. J Biol Chem 1919;40:259-264
17. Loo YH, Potempska A, Wisniewski HM. A biochemical explanation of phenyl acetate neurotoxicity in experimental phenylketonuria. J Neurochem 1985;45:1596-1600
18. Potempska A, Loo YH, Wisniewski HM. On the possible mechanism of phenylacetate neurotoxicity: inhibition of choline acetyltransferase by phenylacetyl-CoA. J Neurochem 1984:42:1499-1501
19. Thibault A, Cooper MR, Rgg WD, Venzon DJ, Sartor AO, Tompkins AC, et al. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 1994;54:1690-1694
20. Burzynski SR. Antineoplastons: history of the research (I). Drugs Exp Clin Res 1986;12(Suppl l):l-9
21. Soltysiak-Pawluczuk D, Burzynski SR. Cellular accumulation of antineoplaston AS2-1 in human hepatoma cells. Cancer Lett 1995; 88:107-112
22. Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, et al. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 1995;75:2932-2938
23. Prados MD, Spence A, Schold C, Robbins I, Mehta M, Berger M, et al. A phase II trial of phenylacetic acid for recurrent malignant glioma: preliminary report of the North American Brain Tumor Consortium [abstract]. Program Proc Am Soc Clin Oncol 1996;15:156